Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCSW) Net Income towards Common Stockholders (2021 - 2025)

Historic Net Income towards Common Stockholders for HeartSciences (HSCSW) over the last 5 years, with Q4 2025 value amounting to -$2.4 million.

  • HeartSciences' Net Income towards Common Stockholders fell 1190.44% to -$2.4 million in Q4 2025 from the same period last year, while for Oct 2025 it was -$9.1 million, marking a year-over-year decrease of 1701.1%. This contributed to the annual value of -$8.9 million for FY2025, which is 3293.13% down from last year.
  • HeartSciences' Net Income towards Common Stockholders amounted to -$2.4 million in Q4 2025, which was down 1190.44% from -$2.1 million recorded in Q3 2025.
  • HeartSciences' 5-year Net Income towards Common Stockholders high stood at -$752051.0 for Q3 2021, and its period low was -$2.6 million during Q1 2025.
  • For the 5-year period, HeartSciences' Net Income towards Common Stockholders averaged around -$1.7 million, with its median value being -$1.8 million (2022).
  • As far as peak fluctuations go, HeartSciences' Net Income towards Common Stockholders plummeted by 10925.5% in 2022, and later surged by 2054.79% in 2023.
  • HeartSciences' Net Income towards Common Stockholders (Quarter) stood at -$1.0 million in 2021, then tumbled by 74.7% to -$1.8 million in 2022, then grew by 3.28% to -$1.7 million in 2023, then fell by 20.26% to -$2.1 million in 2024, then decreased by 11.9% to -$2.4 million in 2025.
  • Its last three reported values are -$2.4 million in Q4 2025, -$2.1 million for Q3 2025, and -$2.1 million during Q2 2025.